Circular RNAs (circRNAs) are the newly uncovered class of non-coding RNAs being recognized as profound regulators of gene expression in developmental and disease biology. These are the covalently closed RNAs synthesized when the pre-mRNA transcripts undergo a back-splicing event. In recent years, circRNAs are gaining special attention in the scientific world and are no longer considered as “splicing noise” but rather structurally stable molecules having multiple biological functions including acting as miRNA sponges, protein decoys/scaffolds, and regulators of transcription and translation. Further, emerging evidence suggests that circRNAs are also differentially expressed in multiple cancers where they play oncogenic roles. In addition, circRNAs in association with miRNAs change the expression patterns of multiple transcription factors (TFs), which play important roles in cancer. Thus, the circRNA-miRNA-TFs axis is implicated in the progression or suppression of various cancer types and plays a role in cell proliferation, invasion, and metastasis. In this review article, we provide an outline of the biogenesis, localization, and functions of circRNAs specifically in cancer. Also, we highlight the regulatory function of the circRNA-miRNA-TFs axis in the progression or suppression of cancer and the targeting of this axis as a potential therapeutic approach for cancer management. We anticipate that our review will contribute to expanding the knowledge of the research community about this recent and rapidly growing field of circRNAs for further thorough investigation which will surely help in the management of deadly disease cancer.

**Keywords:** circrnas, cancer, miRNA sponge, transcription factors, targeted therapy

**Abbreviations:** ABCB1, ATP Binding Cassette Subfamily B Member 1; AMPK, AMP-Activated Protein Kinase; CDC42, Cell Division Cycle 42; CDK6, Cyclin-Dependent Kinase 6; CN-AML, Cytogenetically Normal Acute Myeloid Leukemia; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; CTNNBIP1, Catenin Beta Interacting Protein 1; CXCL10, C-X-C Motif Chemokine Ligand 10; DPP4, Dipeptidyl-Peptidase 4; FBP1, Fructose-Bisphosphatase 1; Hel25E, Helicase at 25E; HIPK3, Homeodomain Interacting Protein Kinase 3; HUVEC, Human Umbilical Vein Endothelial Cells; PABPN1, Polyadenylate-Binding Protein, Nuclear 1; TPT1, Translationally-Controlled Tumor Protein 1; YTHDC1, YTH Domain-Containing protein 1; YTHDF3, YTH N6-Methyladenosine RNA Binding Protein 3.
INTRODUCTION

Cancer involves a broad range of dysregulations in the genome, transcriptome, and proteome. Most of the transcriptome studies related to cancer are concentrated mainly on the changes or dysregulations in the protein-coding genes, focusing less on non-coding RNAs (ncRNAs). These ncRNAs were earlier deemed as “junk of transcription”. But recent studies have reported the emerging contribution of non-coding RNAs in various aspects of carcinogenesis (Singh et al., 2020). According to the length of the transcript, ncRNAs are grouped into small ncRNAs (<200) and long ncRNAs (>200) (Uchida and Adams, 2019). Among the ncRNAs, circular RNAs (circRNA) are a group of endogenous ncRNAs, first discovered in 1976 in the genome of viruses and later found in the cytoplasm of eukaryotic cell lines in 1979 (Sanger et al., 1976; Hsu and Coca-Prados, 1979; Kolakofsky, 1976). Since then, circRNAs remained unexplored due to limitations in technology. However, recent technological advancements and the emergence of techniques such as next-generation sequencing and bioinformatics have led to the identification of the abundance and diversity of circRNAs and their different expression patterns in various physiological conditions is becoming a focus of research. CircRNAs are a group belonging to the large class of ncRNAs produced by a non-canonical splicing event called back-splicing (Chen, 2016). The circRNAs are generated in the nucleus but are exported to and localized predominantly in the cytoplasm (Salzman et al., 2012; Jeck et al., 2013). These are formed by the ligation of the 5’ end of the upstream exon and 3’ end of the downstream exon or the by joining of ends of individual exons. This covalently closed circular structure of circRNAs makes them stable against RNase digestion as compared to the linear RNAs (Enuka et al., 2016). CircRNAs function at various levels of gene regulation. For instance, at transcriptional, splicing, and translational level via acting as miRNA sponge; protein decoys; and by encoding several functional peptides. Recent reports suggest that circRNAs are dysregulated in various diseases including neurological, cardiovascular, immunological diseases, and cancer (Piwecka et al., 2017; Aufero et al., 2019; Kristensen et al., 2019; Vo et al., 2019; Wang et al., 2019).

Interestingly, the accumulation of circRNAs in non-proliferative cells (nervous tissue) and downregulation of circRNAs in proliferative cells have also been reported. During proliferation, circular and linear RNAs are evenly distributed in the daughter cells. The steady-state levels of linear transcripts are regulated mainly due to active transcription and degradation, also resulting in a new expression of circRNAs and constant ratios of circular to linear RNAs (Bachmayr-Heyda et al., 2015). However, the downregulation of circRNAs in proliferating cells is mainly attributed to the dilution of circRNA concentration upon cell division thus reducing the tumor-suppressive potential of circRNAs (Bachmayr-Heyda et al., 2015; Gruner et al., 2016; Vo et al., 2019). In contrast, in non-proliferating cells, linear transcripts are at a steady rate of transcription and degradation while the circRNAs remain stable and accumulate. This negative correlation observed between the abundance of circRNA and proliferation could be used in positioning some of the circRNAs as proliferation markers (Dahl et al., 2021). Further, the upregulated circRNAs could be used to distinguish specific cancer types and as potential indicators of genomic amplification.

CircRNAs are also dysregulated in several human malignancies and represent distinct expression patterns in various cancer types. They are found to be globally reduced in cancerous tissues as compared to the normal tissues possibly due to the following reasons: the compromised back-splicing machinery in the...
cancerous tissues; passive thinning of the circRNAs due to cell proliferation and the increased degradation by miRNAs which are deregulated in the cancerous tissues (Bachmayr-Heyda et al., 2015). CircRNAs have also been reported to play tumor-suppressive or oncogenic roles leading to either the suppression or progression of cancer thereby serving as potential therapeutic targets for cancer diagnosis and treatment (Han et al., 2017; Hu et al., 2018; Chen et al., 2019). For instance, circMTO1 is reported to be downregulated in hepatocellular carcinoma (HCC) (Chen et al., 2019) whereas circPVT1 is found to be upregulated in leukemia (Hu et al., 2018). Further, some of the circRNAs also show inconsistent expression patterns in cancer types. For instance, the circHIPK3 which is transcribed from Exon2 of the HIPK3 gene is upregulated in HCC (Chen et al., 2018a) but it is downregulated in ovarian cancer (Teng et al., 2019). Recent evidence suggests that circRNAs play a significant part in transcriptional control by acting as miRNA sponges and regulating the target genes of miRNAs. miRNAs negatively regulate the expression of the target gene by targeting the 3′UTR of its target mRNA thereby reducing its stability and inhibiting its translation. Thus, several circRNAs have been recently discovered as oncogenic drivers or suppressors of tumorigenesis via the circRNA-miRNA-TF axis. In this review, we will highlight the representative studies depicting the regulatory role of the circRNA-miRNA-TF axis in the initiation or suppression of cancer with the aim of suggesting potential implications for both clinical and therapeutic applications.

**BIOGENESIS AND FUNCTIONS OF CIRCORNAs**

CircRNAs are generated primarily by a non-canonical splicing event called back-splicing, where a downstream splice-donor site is
linked covalently to an upstream splice-acceptor site. (Figure 1). According to the source of origin, circRNAs can be classified into exon derived circRNAs (EcRNAs), exon-intron derived circRNAs (EiCiRNAs), and intron derived circRNAs (Salzman et al., 2013; Zhang et al., 2013; Li et al., 2015a; Lu et al., 2015). The intron-derived circRNAs are further divided into circular intronic RNAs derived from pre-mRNA (ciRNAs) and tRNA intronic circular RNAs (tricRNAs) (Zhang et al., 2013; Lu et al., 2015; Schmidt et al., 2019). The biogenesis of circRNAs involves spliceosomal machinery which ligates the 5′ splice site of an upstream exon to the 3′ splice site of another downstream exon thereby forming a closed structure (Ashwal-Fluss et al., 2014; Starke et al., 2015; Kristensen et al., 2019). This biogenesis is mediated by cis-acting and trans-acting elements. Cis-acting elements function as complementary sequences in the introns which flank the back spliced exons. These cis-acting elements undergo base pairing resulting in the formation of hairpin structure and put forward the 5′ splice site present downstream and 3′ splice site present upstream close enough to enable the easy circularisation of circRNAs (Zhang et al., 2014; Chen, 2016; Wu et al., 2019). The trans-acting factors involved in the biogenesis of circRNAs include RNA binding proteins (RBPs) such as Muscleblind (MBL) and Quaking which recognize and bind to particular regions/motifs within the flanking introns and form a bridge connecting the two splice sites via protein-protein interaction or self-dimerization thereby strengthening the back splicing of introns (Ashwal-Fluss et al., 2014; Conn et al., 2015).

CircRNAs predominantly function as regulatory ncRNAs either at the transcriptional or translational level (Figure 1). CircRNAs associate directly with the RNA Pol II machinery to stimulate the parent gene transcription (Zhang et al., 2013). For instance, RNA-RNA interactions between EcliriRNA and U1 small nuclear ribonucleoproteins (U1 snRNP) result in forming a complex which then interacts with RNA Pol II thereby enhancing the host gene transcription (Li et al., 2015a). CircRNAs also function as miRNA sponges and prevent the miRNA-regulated suppression of the target gene. For instance, circRNA ciRS-7 binds and sponges miR-7 and AGO protein complex to elevate the expression levels of miR-7 targets (Hansen et al., 2013). Further, a single circRNA may have binding sites for multiple miRNAs such as in the case of circSLC8A1 which can sponger both miR-133 and miR-130b/494 (Lim et al., 2019; Lu et al., 2019a). CircRNAs also function as protein decoys in sequestering the proteins. For example, circPABPN1 acts as a competitor of PABPN1 mRNA to bind with HuR thereby suppressing the PABPN1 translation. HuR is an RNA-binding protein having multiple mRNA targets such as TP53, MYC, and HIF-1α (Abdelmohsen et al., 2017; Singh et al., 2021a). Li et al. (2019) reported that circRNAs harbor binding sites for multiple proteins thereby functioning as dynamic protein scaffolds bringing about protein-protein interactions for assembling large RNA-protein complexes. For instance, circACC1 cohere to the β and γ subunits of AMPK resulting in the formation of a ternary complex, thereby stabilizing and promoting the AMPK enzymatic activity (Li et al., 2019).

Although, circRNAs lack a 5′ m7G Cap and 3′ poly (A) tail which are essential for linear transcripts to recruit the initiation factors of translation, circRNAs could undergo cap-independent translation mediated in an m6A modification dependent manner or an internal ribosome entry site (IRES) element dependent manner (Legnini et al., 2017; Yang et al., 2017a). Only a few endogenous circRNAs such as circ-ZNF609, circMbl, circ-FBXW7, circPINTexon2, and circ-SHPRH have been reported to function as templates for translation (Legnini et al., 2017; Pamudurti et al., 2017; Yang et al., 2017b; Yang et al., 2018a; Zhang et al., 2018a; Zhang et al., 2018b). In IRES element-dependent manner, IRES recruit the 40S subunit of the ribosome to RNAs in a 5′ Cap independent manner and enable the translation of many endogenous circRNAs. For instance, YTHDF3 (a reader protein for m6A) binds to the m6A containing circRNAs and further interact with the eIF4G2 and eIF3A translation initiation factors to initiate protein synthesis (Yang et al., 2017b). Since, m6A modifications are present in several circRNAs, whether or not, all of these m6A modified circRNAs having ORFs will be translated in an m6A-dependant manner remains difficult to find and studies are underway to explore this issue. Further, most of the circRNA-derived peptides are truncated forms of canonical proteins and lack essential functional domains, thereby acting as the dominant-negative variants of proteins or as modulators of alternative protein complexes (Legnini et al., 2017). Also, circRNAs are expressed at low levels than the corresponding mRNAs making it difficult to determine whether a circRNA is translated or not. The presence of ORF, functional IRES-like element, and m6A methylation can be used to assess a translated circRNA using luciferase reporters (Legnini et al., 2017; Pamudurti et al., 2017; Yang et al., 2017a; Yang et al., 2018b; Zhang et al., 2018a; Zhang et al., 2018b). Further, polysome profiling and ribosome footprinting can be used to explore whether a circRNA is translated or not (Zhang et al., 2018c).

ABERRANTLY EXPRESSED CIRCNRNAS IN THE PROGRESSION OF VARIOUS CANCER TYPES

CircRNAs show different expression patterns in various human cell types and play physiological roles such as normal cell propagation and hematopoiesis (Bachmayr-Heyda et al., 2015; Bonizzato et al., 2016). CircRNAs also play a role in cancer initiation, progression, and metastasis. Multiple studies have reported the role of circRNAs in numerous cancer types including gastric, colorectal, hepatic, lung, bladder, and prostate cancer (CaP) (Figure 2; Table 1) (Salzman et al., 2013; Bachmayr-Heyda et al., 2015; Bonizzato et al., 2016; Lü et al., 2017). Recently, a genome-wide circRNA microarray study has reported 1,155 aberrantly expressed circRNAs in breast cancer tissues where 715 circRNAs were found to be upregulated and 440 were found to be downregulated (Lü et al., 2017). Another circRNA microarray study in pancreatic ductal adenocarcinoma (PDAC) reported an upregulation of 209 circRNAs and downregulation of 142 circRNAs (Li et al., 2016).
In breast cancer tissues, circ-MYO9B has been reported to be overexpressed. Further, specific silencing of circ-MYO9B resulted in a suppression of cancer cell proliferation, invasion, and metastasis in MCF7 and MDA-231 breast cancer cells. Mechanistically, it has been reported that circ-MYO9B sponges miR-4316 and enhances FOXP4 levels thereby promoting breast cancer progression and highlighting the key role of circ-MYO9B/miR-4316/FOXP4 axis in breast cancer (Wang et al., 2018a; Zhang and Zhang et al., 2019). Califf, (2018) reported that downregulation of circ-ITGA7 is associated with the progression of colorectal cancer (CRC). Further, the overexpression of circ-ITGA7 resulted in the inhibition of CRC cell proliferation and metastasis both in vitro and in vivo. Kong et al. (2017) reported the circ-SMARCA5 to function as an oncogenic circRNA in CaP via promoting cell proliferation and inhibiting apoptotic cell death. Here, the silencing of circ-SMARCA5 in Du-145 CaP cells resulted in inhibition of cell proliferation and induction of apoptosis (Kong et al., 2017). All these shreds of evidence indicate the involvement of circRNAs in cancer progression and recommend that targeting of circRNAs for cancer therapeutics could be beneficial in combating this deadly disease.

**CIRCRNA-MIRNA-TFS AXIS IN CANCER PROGRESSION AND SUPPRESSION**

Several studies have identified the sponging action of circular RNA on micro RNA (miRNA) as miRNA sponges as well as uncovered the circular RNA-miRNA-mRNA axis which activates pathways associated with various cancers (Sui et al., 2017). The network of circRNA, miRNA, and TFs play a role in the progression of cancer suggesting an undeviating link between the regulatory properties among the circRNA-miRNA-TF network (Sui et al., 2017). CircRNAs act as transcriptional regulators by sponging miRNAs and modulating the expression of the targets of miRNAs. For instance, cerebellar degeneration-related
protein 1 antisense transcript (CDR1as) also termed as ciRS-7 (circular RNA sponge for miR-7) is the best-known circRNA which has been uncovered as a regulator of cellular processes and has over 70 binding sites for miR-7 (Hansen et al., 2013; Memczak et al., 2013). According to the competing endogenous RNA (ceRNA) hypothesis, CDR1as acts as a negative regulator of miR-7 (a widely studied tumor suppressor) and also influences several gene activities (Salmena et al., 2011; Hansen et al., 2013; Memczak et al., 2013; Tay et al., 2014) thereby making CDR1as a focus of cancer research (Kefas et al., 2008; Jung et al., 2012; Kong et al., 2012; Suto et al., 2015). For instance, ccrPRMT5 via sponging miR-30c promotes the expression of SNAIL and TWIST which stimulate EMT via enhancing the expression of N-Cadherin/Vimentin and inhibiting E-CADHERIN. Circ-CTNNB1 binds to DDX3 facilitating the interaction of DDX3 with YY1 thereby transactivating YY1 and enhancing the expression of WNT1 and WNT3 which further bind to Frizzled receptor leading to amplification of Wnt/ß-Catenin pathway. Amplified Wnt/ß-Catenin signaling inhibits GSK3ß mediated destruction of ß-catenin, allowing translocation of cytoplasmic ß-Catenin to nucleus and initiation of transcription of the effectors involved in the process of EMT. circ ß-Catenin acts as a decoy for GSK3ß and protects ß-Catenin from the GSK3ß mediated degradation resulting in the promotion of Wnt/ß-Catenin signaling and EMT in HCC. Circ-FOXO3 plays a pro-apoptotic role via sponging miR-22 and miR-138. Circ-UBAP2 and circOMA1 play anti-apoptotic roles by sponging miR-143 and decoying miR-145-5p respectively. The expression of HIF-1α is regulated by PI3K/AKT pathway. HIF-1α promotes the expression of VEGF thereby promoting angiogenesis. An upregulated circ_0010729 sponges miR-186 and inhibit the miR-186 mediated degradation of HIF-1α thus promoting angiogenesis. Circ-MYLK serves as a decoy for miR-29a and promotes the stability of VEGF resulting in angiogenesis.

FIGURE 3 | A diagrammatic illustration of the circRNA-miRNA-TF signaling axis in the progression or suppression of cancer. c-Myc, a cell cycle regulator is modulated by circMT01 and circTCH4 via sponging miR-9, miR-17/miR-224 resulting in an enhanced p21 level and cell cycle progression. Increased expression of Circ-ZNF609 also promotes cell proliferation via c-Myc. The expression of pro-tumorigenic SNAIL and TWIST is also regulated by circRNA which interacts with the signaling pathways and promotes EMT. For instance, ccrPRMT5 via sponging miR-30c promotes the expression of SNAIL and TWIST which stimulate EMT via enhancing the expression of N-Cadherin/Vimentin and inhibiting E-CADHERIN. Circ-CTNNB1 binds to DDX3 facilitating the interaction of DDX3 with YY1 thereby transactivating YY1 and enhancing the expression of WNT1 and WNT3 which further bind to Frizzled receptor leading to amplification of Wnt/ß-Catenin pathway. Amplified Wnt/ß-Catenin signaling inhibits GSK3ß mediated destruction of ß-catenin, allowing translocation of cytoplasmic ß-Catenin to nucleus and initiation of transcription of the effectors involved in the process of EMT. circ ß-Catenin acts as a decoy for GSK3ß and protects ß-Catenin from the GSK3ß mediated degradation resulting in the promotion of Wnt/ß-Catenin signaling and EMT in HCC. Circ-FOXO3 plays a pro-apoptotic role via sponging miR-22 and miR-138. Circ-UBAP2 and circOMA1 play anti-apoptotic roles by sponging miR-143 and decoying miR-145-5p respectively. The expression of HIF-1α is regulated by PI3K/AKT pathway. HIF-1α promotes the expression of VEGF thereby promoting angiogenesis. An upregulated circ_0010729 sponges miR-186 and inhibit the miR-186 mediated degradation of HIF-1α thus promoting angiogenesis. Circ-MYLK serves as a decoy for miR-29a and promotes the stability of VEGF resulting in angiogenesis.

CircRNA-miRNA-C-MYC

The oncogenic MYC family has been implicated to be upregulated or aberrantly expressed in more than half of human cancers thereby playing an important role in cancer initiation and maintenance (Fatma and Siddique, 2020). c-MYC is one of the key TFs and accelerators of the cell cycle which plays a role in cell proliferation and is upregulated in various cancer types. Similarly, circRNAs have been reported to interfere with the regulatory cell cycle network...
leading to escape from cell cycle inhibitors and the generation of sustained proliferative signaling in several cancer types. Yang et al., 2017a reported that upregulated expression of Circ-Amotl1 promotes the growth and proliferation of breast cancer. Further, Circ-Amotl1 interacts with c-MYC and enables the retention and stability of c-MYC inside the nucleus and the resultant upregulation of c-MYC targets (Yang et al., 2017b). Another circRNA, circCCDC66 has been depicted to be aberrantly expressed in CRC. Here, an upregulation of circCCDC66 prevents the degradation of c-MYC mRNA via sponging miR-33b/miR-93 and resulting in the elevation of c-MYC levels and promotion of tumor cell growth and proliferation (Hsiao et al., 2017). Recently, Zhao et al. (2020) also reported an ectopic overexpression of circUHRF1 in oral squamous cell carcinoma. CircUHRF1 shows a sponging action towards miR-526b-5p which targets c-MYC expression. Thus, circUHRF1 regulates EMT progression of OSCC via the circUHRF1/miR-526b-5p/c-MYC axis. In another study on triple-negative breast cancer (TNBC), the upregulation of circ-PGAP3 was found to negatively correlate with miR-330-3p expression and positively correlate with the protein level of MYC. This study reported that circ-PGAP3 promotes TNBC growth and metastasis via sponging and inhibiting miR-330-3p and concomitant upregulation of c-MYC (He et al., 2020).

Circ-FBXW7 has also been reported to be involved in the reduction of c-MYC half-life via encoding a functional protein namely FBXW7-185aa. Mechanistically, the c-MYC protein level is maintained via the ubiquitin-proteasome pathway involving an E3 ligase FBXW7α and a ubiquitin-specific protease USP28. USP28 interact with the N-terminal domain of FBXW7α and results in antagonizing the c-MYC ubiquitylation and degradation. Interestingly, circ-FBXW7 encoded functional protein (FBXW7-185aa) shares the same 167 amino acid sequence with the N-terminal sequence of FBXW7α and as a result competes with FBXW7α leads to FBXW7α mediated degradation of c-MYC. Thus, a reduction in the expression of circ-FBXW7α will lead to an increase in the expression of oncogenic c-MYC and ultimate proliferation and invasion of glioblastoma (Yang et al., 2018a). circFBXW7 has also been reported to directly sponge miR-197-3p, mitigate the silencing of FBXW7α and inhibit the TNBC progression by increasing the abundance of FBXW7α and promoting the degradation of c-MYC (Ye et al., 2019). In HCC and bladder carcinoma, circRNA circMTO1 and circITCH have been reported to stabilize the levels of p21 mRNA (a downstream target of c-MYC) via sponging of miR-9/miR-17/miR-224, resulting in an increase in the level of p21. Thus, any downregulation in the levels of these circRNAs will result in the progression of HCC or bladder cancer (Han et al., 2017b, Yang et al., 2018b).

### TABLE 2: Regulatory role of the circRNA-miRNA-TFs axis in various aspects of carcinogenesis.

| S.No. | CircRNA | Cancer type | miRNA | Target mRNA | Outcome | References |
|-------|---------|-------------|-------|-------------|---------|------------|
| 1 | CircPTK2 | NSCLC | miR-429/miR-200b-3p | TIF1γ | Inhibits cancer proliferation and EMT | Wang et al. (2018b) |
| 2 | CircHIPK3 | Colorectal | miR-7 | YY1 | Promotes cancer progression | Zeng et al. (2018) |
| 3 | CircANKS1B | Breast | miR-148a-3p/miR-152-3p | EGFR/FAK | Inhibits cancer cell apoptosis | Zeng et al. (2018) |
| 4 | CircFBXW7 | Glioblastoma | FBXW7-185aa | c-MYC | Promotes cancer growth, invasion, and EMT | Yang et al. (2018a) |
| 5 | Circ-CYSL | HCC | miR-892a/328-3p | HDGF/HIF1α | Promotes cancer cell growth and propagation | Wei et al. (2020) |
| 6 | CircMTO1 | HCC | miR-9 | p21 | Inhibits cancer progression | Han et al. (2017) |
| 7 | Circ-TCP25 | Bladder | miR-103-3p/miR-107 | CDK6 | Promotes cancer progression | Zhang et al. (2016) |
| 8 | Circ-ITCH | Bladder | miR-17/miR-224 | P21 | Promotes cancer progression | Yang et al. (2018b) |
| 9 | CircAmot1 | Prostate | miR-193a-5p | pcdha | Inhibition of EMT | Yang et al. (2019a) |
| 10 | Circ-FOXO3 | Breast | miR-138 | P53 | Promotes apoptosis of cancer cells | Du et al. (2017) |
| 11 | Circ-HIAT1 | Renal | miR-29c-3p/miR-195-5p/miR-29a-3p | CDC42 | Promotes cancer invasion and metastasis | Wang et al. (2019) |
| 12 | CircNRIP1 | Gastric | miR-149-5p | AKT/mTOR | Promotes cancer proliferation and invasion | Zhang and Zhang et al. (2019) |
| 13 | CircCCDC66 | Colorectal | miR-33b/93 | MYC | Promotes cancer growth, invasion, and metastasis | Hsiao et al. (2017) |
| 14 | CircPRMT5 | Bladder | miR-30c | SNAIL | Promotes EMT and metastasis | Chen et al. (2018b) |
| 15 | CircUBAP2 | Osteosarcoma | miR-143 | Bcl-2 | Promotes cancer proliferation | Zhang et al. (2017) |
| 16 | CircOMA1 | Pituitary adenoma | miR-145-5p | TPT1 | Inhibition of apoptosis and promotion of cancer progression | Du et al. (2019) |
| 17 | Circ_001079 | HUVEC | miR-186 | HIF-1α | Promotes cancer proliferation and angiogenesis | Dang et al. (2017) |
CircRNA-miRNA-TGF-β/SMAD

TGF-β signaling is actively involved in tumor metastasis and transition of Epithelial state to mesenchymal state (EMT) in various human cancers (Kaminska and Cyranowski, 2020). EMT is under the regulatory role of upstream signaling pathway viz. TGF-β/SMAD. CircRNAs have been reported to interfere with EMT and tumor metastasis via participating in the TGF-β signaling. For instance, circANKS1B has been reported to be upregulated in TNBC where it sponges miR-148a-3p/miR-152-3p to enhance the expression levels of a TF, USF1 which further results in upregulating TGF-β expression and then TGF-β/SMAD regulated EMT (Zeng et al., 2018). On the contrary, circPTK2 has also been reported to sequester miR-629, a miRNA involved in EMT inhibited migration, invasion, and EMT. Here, a decrease in the expression of circPTK2 promotes invasion and metastasis in non-small cell lung cancer (NSCLC) (Wang et al., 2018b). In study, Zhang et al. (2018a) investigated the relationship between circSMAD2 and HCC cells/tissues. The group observed that circSMAD2 was downregulated in HCC tissues and this downregulation correlates with the level of tumor differentiation where lower levels of circSMAD2 were found in the poorly differentiated HCC tissues. SMAD2, the gene from which circSMAD2 is generated plays a key role in EMT and HCC progression (Heldin and Moustakas, 2012). Further, the upregulation of circSMAD2 is also observed during the TGF-β induced EMT (Conn et al., 2015). In contrast to this, Zhang et al. (2018b) observed that upregulated circSMAD2 in HCC cells inhibited migration, invasion, and EMT. Here, circSMAD2 sponges miR-629, a miRNA involved in EMT via downregulating the tripartite motif-containing 33 (TRIM33) expression and promoting the TGF-β/SMAD2 signalling. Thus, circSMAD2 sponges miR-629 and inhibit the invasion, migration, and EMT in HCC cancer cells via the TGF-β/SMAD2 signalling (Zhang et al., 2018d). However, the study was in vitro and requires further in vivo validation.

Huang et al. (2020a) introduced the involvement of circRNA, cESRP1 in small cell lung cancer (SCLC). They reported for the first time that cESRP1 plays a regulatory role in chemosensitivity of SCLC via sponging miR-93-5p-3p/SMAD7/p21 axis and inhibiting TGF-β mediated EMT in SCLC. Another circRNA viz. circ-OXCT1 has been reported to be downregulated in GC cell lines and tissues and this downregulation is associated with lymph node metastasis and survival rate (Liu et al., 2020). Further, the data suggest that overexpression of circ-OXCT1 in gastric cancer suppresses EMT and metastasis via the TGF-β/SMAD signaling pathway. Here, knockdown of circ-OXCT1 downregulated the expression of SMAD4 via sponging miR-136 and consequently regulated the levels of E-Cadherin, N-Cadherin, and Vimentin via the TGF-β/SMAD signaling pathway resulting in promoting EMT, and cancer (Liu et al., 2020). Thus, the clinicopathological studies and data suggest the circ-RNA-TGF-β axis as a potential target for treating advanced-stage carcinoma. Further, Shang et al. (2020) reported the circPACRG1 mediated progression of CRC cells through the miR-142-3p/miR-506-3p/TGF-β axis. The group reported that cancer-derived exosomal circPACRG1 acts as a miRNA sponge for miR-142-3p/miR-506-3p and stimulate the expression of TGF-β1 in CRC cell proliferation, invasion, and migration. Xu et al. (2020) reported another circRNA, CCDC66 which is upregulated in gastric cancer tissues and this upregulation correlates with the concomitant triggering of the TGF-β pathway and tumor progression. Further, the knockdown of circCCDC66 resulted in inducing programmed cell death and suppressing gastric cancer growth.

CircRNA-miRNA-SNAIL/TWIST

SNAIL and TWIST are the principal transcription factors in the TGF-β/SMAD and Wnt/β-Catenin signalling pathways. SNAIL and TWIST are critical EMT-inducing TFs that increase the expression levels of Vimentin (Mahmood et al., 2017). Recently, circRNAs have been reported to crosstalk with these TFs involved in the EMT process. For instance, in bladder urothelial carcinoma, circPRMT5 is reported to be involved in the promotion of EMT and cancer cell metastasis via sponging and elevation of miR-30c and SNAIL, respectively (Shibue and Weinberg, 2017; Chen et al., 2018b). circMET is another circRNA that is upregulated in HCC tumors and the aberrant expression of circMET correlates with the tumor recurrence in HCC patients. Mechanistically, circMET overexpression promotes EMT and result in lowering the immune response by inducing an immunosuppressive microenvironment in HCC patients through the miR-30-5p/Snail/(DPP4)/CXCL10 axis (Huang et al., 2020b). Mechanistically, DPP4, a downstream target of SNAIL is involved in immune suppression via negative regulation of the lymphocyte trafficking. DDP4 cleaves CXCL10 chemokine which is important in determining the trafficking of effector T-cells to the tumor microenvironment. The inhibition of DPP4 preserves the CXCL10 chemokine and enhances the tumor immunity and the migration of T-cells to the tumor microenvironment. Thus, the study revealed that circMET acts as an onco-circRNA via the miR-30-5p/SNAIL/DPP4/CXCL10 axis. (Holland et al., 2019), Guo et al. (2019) reported an upregulated circ-ZNF652 acting as a prognostic marker for HCC patients. Circ-ZNF652 increases the expression of EMT trigger SNAIL via the sponging of miR-203/miR-502-5p thereby promoting metastasis in HCC. Further, the knockdown of circ-ZNF652 led to a reduction in the metastatic capability of HCC cells both in vitro and in vivo conditions. Mechanistically, the circuitry involved here includes SNAIL which binds directly to the E-box motif (CAGGTG) present on the promoter of circ-ZNF652 thereby enhancing circ-ZNF652 levels (Guo et al., 2019). Thus, the circ-ZNF652/miR-203/miR-502-5p/SNAIL axis would be a potential target for HCC management and treatment. circFNDC3B-218aa has also been depicted to play an inhibitory role in the progression of CRC. Here, circFNDC3B-218aa inhibits the expression of SNAIL and subsequently upregulates FBPI expression thereby.
inhibiting EMT in CRC and acting as a therapeutical target for CRC (Pan et al., 2020). CircRNA_0084043 is another circRNA that is significantly upregulated in melanoma tissue and promotes the cancer progression and metastasis via directly binding and sponging miR-153-3p and leading to the upregulation of SNAIL thereby functioning as an oncogene in melanoma (Luan et al., 2018).

TWIST has also been reported to regulate the expression of circRNA in the induction of EMT. TWIST binds and activates the transcription of the Cul2 promoter leading to the expression of Cul2 circular RNA (circ-10720) and the resultant sponging of miR-490-5p, a miRNA involved in targeting and suppressing Vimentin (an EMT marker). Thus, TWIST indirectly leads to the induction of EMT via the cul2/miR-490-5p axis (Meng et al., 2018). Similarly, circAMOTL1L has been reported to upregulate E-cadherin and downregulate Vimentin resulting in the inhibition of EMT and CaP progression (Yang et al., 2019a).

**CircRNA-miRNA-FOXO3**

Forkhead box 3 (FOXO3) protein belongs to the FOXO subclass of TF. FOXO3 mediates several biological processes including cell propagation, DNA damage, apoptosis, and tumorigenesis (Liu et al., 2018a). FOXO3 also leads to the induction of apoptosis via upregulation of PUMA (a pro-apoptotic protein). It has been reported that circRNA i.e. circ-FOXO3 performs a prosapoptotic role via promoting FOXO3 expression (Du et al., 2017). Mechanistically, circ-FOXO3 forms a complex with p53 (tumor suppressor gene) and MDM2 resulting in the aggravation of MDM2-induced degradation of p53 and protecting FOXO3 from suppressor gene (and MDM2 resulting in the aggravation of)

Mechanistically, circ-FOXO3 forms a complex with MDM2 dependent degradation. Later, FOXO3 leads to the induction of EMT via the cul2/miR-490-5p axis (Meng et al., 2018). Similarly, circAMOTL1L has been reported to upregulate E-cadherin and downregulate Vimentin resulting in the inhibition of EMT and CaP progression (Yang et al., 2019a).

**CircRNA-miRNA-FOXO3**

Forkhead box 3 (FOXO3) protein belongs to the FOXO subclass of TF. FOXO3 mediates several biological processes including cell propagation, DNA damage, apoptosis, and tumorigenesis (Liu et al., 2018a). FOXO3 also leads to the induction of apoptosis via upregulation of PUMA (a pro-apoptotic protein). It has been reported that circRNA i.e. circ-FOXO3 performs a prosapoptotic role via promoting FOXO3 expression (Du et al., 2017). Mechanistically, circ-FOXO3 forms a complex with p53 (tumor suppressor gene) and MDM2 resulting in the aggravation of MDM2-induced degradation of p53 and protecting FOXO3 from suppressor gene (and MDM2 resulting in the aggravation of)

Mechanistically, circ-FOXO3 forms a complex with MDM2 dependent degradation. Later, FOXO3 leads to the induction of EMT via the cul2/miR-490-5p axis (Meng et al., 2018). Similarly, circAMOTL1L has been reported to upregulate E-cadherin and downregulate Vimentin resulting in the inhibition of EMT and CaP progression (Yang et al., 2019a).

**CircRNA-miRNA-FOXO3**

Forkhead box 3 (FOXO3) protein belongs to the FOXO subclass of TF. FOXO3 mediates several biological processes including cell propagation, DNA damage, apoptosis, and tumorigenesis (Liu et al., 2018a). FOXO3 also leads to the induction of apoptosis via upregulation of PUMA (a pro-apoptotic protein). It has been reported that circRNA i.e. circ-FOXO3 performs a prosapoptotic role via promoting FOXO3 expression (Du et al., 2017). Mechanistically, circ-FOXO3 forms a complex with p53 (tumor suppressor gene) and MDM2 resulting in the aggravation of MDM2-induced degradation of p53 and protecting FOXO3 from suppressor gene (and MDM2 resulting in the aggravation of)

Mechanistically, circ-FOXO3 forms a complex with MDM2 dependent degradation. Later, FOXO3 leads to the induction of EMT via the cul2/miR-490-5p axis (Meng et al., 2018). Similarly, circAMOTL1L has been reported to upregulate E-cadherin and downregulate Vimentin resulting in the inhibition of EMT and CaP progression (Yang et al., 2019a).

**CircRNA-miRNA-FOXO3**

Forkhead box 3 (FOXO3) protein belongs to the FOXO subclass of TF. FOXO3 mediates several biological processes including cell propagation, DNA damage, apoptosis, and tumorigenesis (Liu et al., 2018a). FOXO3 also leads to the induction of apoptosis via upregulation of PUMA (a pro-apoptotic protein). It has been reported that circRNA i.e. circ-FOXO3 performs a prosapoptotic role via promoting FOXO3 expression (Du et al., 2017). Mechanistically, circ-FOXO3 forms a complex with p53 (tumor suppressor gene) and MDM2 resulting in the aggravation of MDM2-induced degradation of p53 and protecting FOXO3 from suppressor gene (and MDM2 resulting in the aggravation of)

Mechanistically, circ-FOXO3 forms a complex with MDM2 dependent degradation. Later, FOXO3 leads to the induction of EMT via the cul2/miR-490-5p axis (Meng et al., 2018). Similarly, circAMOTL1L has been reported to upregulate E-cadherin and downregulate Vimentin resulting in the inhibition of EMT and CaP progression (Yang et al., 2019a).

**CircRNA-miRNA-FOXO3**

Forkhead box 3 (FOXO3) protein belongs to the FOXO subclass of TF. FOXO3 mediates several biological processes including cell propagation, DNA damage, apoptosis, and tumorigenesis (Liu et al., 2018a). FOXO3 also leads to the induction of apoptosis via upregulation of PUMA (a pro-apoptotic protein). It has been reported that circRNA i.e. circ-FOXO3 performs a prosapoptotic role via promoting FOXO3 expression (Du et al., 2017). Mechanistically, circ-FOXO3 forms a complex with p53 (tumor suppressor gene) and MDM2 resulting in the aggravation of MDM2-induced degradation of p53 and protecting FOXO3 from suppressor gene (and MDM2 resulting in the aggravation of)
Catenin pathways. These include circRNA_102171, circ_0067934, and circRNA_100290 which activate the Wnt signaling pathway by sponging CTNNBP1, miR-1324, and miR-516 and thereby promoting the progression, invasion, and metastasis of thyroid, liver, and CRC, respectively (Bi et al., 2018; Fang et al., 2018; Zhu et al., 2018). In contrast, circ_0006427 inactivates the Wnt signaling pathway through sponging miR-6783-3p and consequently suppressing the progression of lung adenocarcinoma (Yao et al., 2019).

**CircRNA-miRNA-HIF-1α**

Hypoxia-inducible factor-1α (HIF-1α) is another important transcription factor that functions in response to hypoxic conditions and promotes the expression of genes related to angiogenesis such as vascular endothelial growth factor (VEGF), a predominant growth factor involved in promoting the endothelial cell proliferation to form blood vessels (Apte et al., 2019). HIF-1α has been recently reported to be regulated by circRNAs. Dang et al. (2017) reported that circ_0010729 is upregulated under hypoxic conditions and sponges miR-186 to inhibit the miR-186 regulated degradation of HIF-1α thereby allowing the HIF-1α expression and facilitating angiogenesis. The circ-HIPK3 is another circRNA that acts as a competing endogenous RNA and functions in cancer progression and metastasis via sponging miR-338-3p and enhancing the HIF-1α levels resulting in HIF-1α mediated EMT of cervical cancer (Qian et al., 2020). Another study has reported that circRNA_100859 is significantly overexpressed in colon cancer and functions as an oncogene in the proliferation of colon cancer. The use of the circNET database in this study revealed that miR-217 is a target of this circRNA. Circ_100859 sponges miR-217 which further directly targets the HIF-1α gene and promotes colon cancer progression via this circ_100859/miR-217/HIF-1α axis (Zhou et al., 2020). In HCC, hsa_circ_0046600 is highly upregulated and this upregulation is found to correlate with the tumor size and vascular invasion in HCC patients. This has been reported to occur via the circRNA/miRNA/TF axis. Here, hsa_circ_0046600 sponges and inhibits miR-640 thereby promoting the expression of HIF-1α and progression of HCC (Zhai et al., 2019). The above evidence suggests the emerging role of circRNA as cancer biomarkers and the potential of the circRNA-miRNA-TFs axis as a therapeutic target for cancer management.

**CIRC RNA-MIRNA-TF AXIS BASED TARGETED THERAPEUTIC STRATEGIES FOR CANCER TREATMENT**

The circRNA-miRNA-TFs axis has a crucial role in the progression or suppression of cancer. As circRNA has several miRNAs binding sites, targeting and inhibiting circRNAs may serve as a potential and more beneficial therapeutic approach than targeting or inhibiting a single miRNA/gene. The most common approach for determining the functions of circRNA is RNA interference (RNAi). RNAi follows a loss-of-function approach to determine the functions of circRNA. For this purpose, the viral vector packaged circRNA transcripts could be delivered to the target cells to explore their therapeutic effects (Huang et al., 2019). The inhibition of the specific circRNA will help in enhancing the protective action of the miRNA in the inhibition of oncogenes such as β-catenin (Xia et al., 2018; Shang et al., 2019; Chen et al., 2020a; Chen et al., 2020b). Further, the CRISPR/Cas9 mediated technology of genetic engineering also serves as a novel tool in the investigation of circRNAs. The CRISPR/Cas-meditated homologous recombination may lead to the replacement of a circRNA gene with a marker gene thereby resulting in the consumption of circRNA without affecting the existing gene (Ho et al., 2015). For this purpose, the investigation and screening of circRNA with libraries equipped with distinct guide RNA (gRNA) will help in boosting targeted therapies.

The current targeted strategy for circRNA could involve the synthesis of a circRNA sponge using the approach of simple enzymatic ligation. The artificially synthesized circRNA molecule could be exogenously applied as a miRNA inhibitor to facilitate the binding as well as blocking of miRNA maturation thereby serving as a propitious cancer management approach (Liu et al., 2018b). In a study, Jost et al. (2018) artificially engineered the miR-122 sequestering circRNA sponges in vitro and isolated miR-122 from the Hepatitis C Virus (HCV). Further, circRNAs can also be exploited in sponging proteins. The bindings sites procured from CLIP and SELEX data can be utilized for many RBPs (Jost et al., 2018). The circular miR-122 RNA sponge against HCV could be employed in combination with the sequences that sequester the host factors (hnrNP L and HuR) which are required for the propagation of HCV. Thus, the artificially engineered circRNA sponge may function as a promising tool in circRNA-based targeted anti-tumor therapy and has a potential application in molecular medicine and therapeutics.

Exosomes are also a burning topic in the field of cancer-based research and therapy, which serves as a delivery vehicle for circRNA, lncRNA, mRNA, miRNA, and other proteins and lipids (Shi et al., 2020). Furthermore, the roles of exosome-derived circRNAs have also been reported to be used as biomarkers in clinical applications (Wang et al., 2020a). They usually range from 30 to 100 nm in diameter. Importantly, neoplastic cells secrete a great number of exosomes (10 times) than other cells of the biological system (Xiong et al., 2019). In a study by Wang and their team, exosomes derived from CRC cells upregulated PKM2 via microsponging of miR-122 by ciRS-122 circRNA. The up-regulation of PKM2 releases more energy (due to liberation of ATP and glycolysis) for transporters which eject the drug out of the cell. It was also found that ciRS-122 delivered via exosomes to non-chemo resistant cells enhances the drug resistance. Taking advantage of this study, exosomes based delivery of siRNA to ciRS-122 circRNA was designed that elevate the level of miR-122 and decrease the level of PKM2 influencing the sensitivity of oxaliplatin (a platinum-based chemotherapeutic agent) in mice (Wang et al., 2020b). Exosomes could also transmit circ_0051443 from normal to HCC cells resulting in inhibiting the malignant nature of HCC via the induction of programmed cell death and cell cycle arrest (Chen et al., 2020). Here, circ_0051443 reduced the tumor size and volume via the upregulation of BAK1.
Interestingly, emerging shreds of evidence have portrayed the therapeutic function of circRNA encoded tumor-related functional peptides. These functional peptides include cancer-inhibiting proteins or peptides such as circ β-Catenin encoded β-Catenin-370aa; circ-AKT3 encoded AKT3-174aa; circPPP1R12A encoded circPPP1R12A-73aa (Wu et al., 2020). These functional peptides encoded by circRNAs play predominant roles in carcinogenesis making them novel targets for cancer treatment and drug development (Wu et al., 2020). The clinical significance of these circRNA encoded functional peptides enable the use of these peptides in the treatment of cancer shortly. For this purpose, an appropriate delivery system is required for the transportation of both artificially engineered circRNA and the functional peptides to the target cell. The emerging field of nanomedicine and the development of nanoparticles-based preparations could improve the intracellular entry of therapeutic cargos (Khan et al., 2021). Nanoparticles could be used as an efficient drug delivery molecule for the treatment and management of cancer in many ways such as through intravenous and tail vein injection thereby serving as a promising tool for therapeutic purposes. A recent plasmid-based delivery system has been established by Yi et al. (2020) viz. the Micropoly-transfecter which is capable of delivering circ-1073 plasmid via intratumoral injection resulting in the inhibition of tumor development. Presently, the circRNA mediated targeted cancer therapy is still in its beginning stage, and therefore more extensive research needs to be done to unfold the use of the circRNA-miRNA-TF axis as a therapeutic target.

**NANOMEDICINE: A HOPE TO TARGET THE CIRCRNA-MIRNA-TF AXIS**

Targeted therapies have gained widespread attention in cancer management (Ke and Wu, 2016). However, the demand for safe and 100 percent effective treatment is still a lag. The development of nanoparticles-based drug delivery molecules could improve the delivery of circRNA based therapeutic cargos. Through in vivo studies, nanoparticle-based delivery systems have elevated the feasibility of circRNA. Recently, Du et al. (2018) designed a bifunctional therapeutic approach against breast cancer. Gold nanoparticles conjugated with siRNA targeting CircDnmnt1 or anti-sense oligonucleotide (AON) targeting binding site over circDnmnt1 meant for p53 and Aa1 was constructed, which resulted in the suppression of tumor cells and enhanced cellular autophagy and survival of mice (Du et al., 2018; Zhang et al., 2020). Furthermore, the deliverance of circFOXO3 plasmid through gold nanoparticles helped in the repression of tumor metastasis (Du et al., 2017). In another study, the tumor growth and mouse survival were increased after the treatment with targeted delivery of gold nanoparticles for AON blocking binding site on circCCNB1 for CDK1 and CCNB1 (Fang et al., 2019). Thus, from these studies, we speculate that nanoparticle-based delivery of circRNA-miRNA based therapy could provide a new way of treatment to chemoresistant and non-chemoresistant cancer. However, it further requires more extensive studies using various cancer animal models (khan et al., 2019).

**CONCLUSION AND FUTURE PERSPECTIVE**

In the past few years, circRNAs have evolved as a new puzzle and a focus of research in cancer biology and therapy. Despite great progress in the characterization of circRNA, many factors still exist to be explored. Firstly, cancer-related available database RNA-seq data sets are put together applying a poly-A purification step to specifically enrich the mRNAs. This purification step reduces the possibility of identification of circRNAs that lack a poly-A tail (Kristensen et al., 2018). Next, circRNA discovery involves circRNA detection and quantification which might be affected by template switching artifacts (which mimics linear splicing and back splicing) and rolling circle amplification during RT-PCR (Szabo and Salzman, 2016). Some studies reported that circRNAs dysregulations in cancer are due to abnormal biogenesis. Studies need to be done to identify the detailed mechanism of production and turnover of circRNA which will contribute to understanding the circRNA dysregulation in cancer. Further, miRNA sponging has been considered a common mechanism of action of circRNA. For instance, CDRIAs and circular Sry RNA function as efficient miRNA sponges in the regulation of gene expression. However, this sponging action faces challenges as few circRNAs harbor numerous miRNA binding sites for one miRNA such as in the case of CDRIAs and circular Sry RNA (Guo, 2014). Further, the abundance of several circRNAs is lower than that of miRNAs making it difficult to achieve the miRNA sponging effect. Thus, the stoichiometric relevance between the miRNA-binding site of the sponge and the ultimate miRNA target site should be carefully taken into consideration. For the validation of the proposed sponging functioning, Ago-CLIP and luciferase reporter assays would be beneficial. Next, some studies conflict with the miRNA sponging action of circRNAs. For instance, Kristensen et al. (2020) reported that the putative oncogenic ciRS-7 that is abundant in tumors is not expressed in the colon tumor cells but the stromal cells within the tumor microenvironment relative to the uninvolved stromal cells. The high ciRS-7 expression in the tumor stromal cells is correlated with poor prognosis. Further, the correlation established between circRNA and mRNA expression which is generally interpreted as evidence of ceRNA function is also controversial. ciRS-7 correlates with the expression of miR-7 target genes depending on whether they are co-expressed or mutually exclusive in cancer or stromal cells (Kristensen et al., 2020). Therefore, extensive and more challenging studies on circRNAs need to be done to carefully establish the exact functioning and expression patterns of circRNAs in cancer progression.

Further, most of the circRNAs are lowly expressed and are unlikely to have functional relevance. A group of researchers has reported that there is no association of circRNAs with polysomes (Guo et al., 2014; You et al., 2015), arguing against the notion that circRNAs function through their
protein products (Kristensen et al., 2019). Further, the translation of circRNA depends on IRES, but IRES is present only in <1.5% circRNAs (Fan et al., 2019). It is noteworthy that circRNA translation also does not confirm its advantage as translation could itself be an error due to fallacious initiation and the resultant protein product could be functionless or malignant. Therefore, extensive studies on establishing the functional relevance of circRNAs and their products need to be done. Moreover, most of the differentially expressed circRNAs in cancer may not necessarily be cancer drivers. For instance, the brain shows more back-spliced genes and has a higher back slicing rate than the heart, kidney, liver, or any other organ (Xu and Zhang, 2021). This observation however does not necessarily support the proposal that circRNAs play important roles in the brain (Rybak-Wolf et al., 2015). In the brain, the rate of back-splicing is still very low and the fraction of deleterious back-splicing is atleast 73.2% (Xu and Zhang, 2021). Further, brain cells have a longer life span than any other cells leading to the accumulation of circRNAs at a higher level than other tissues. Taken together, back-splicing events may be splicing errors. Therefore, circRNAs produced by back-splicing events may be functional or non-functional and the aberrant or high expressions of circRNAs do not necessarily indicate their relevance in cancer progression.

Next, if the balance between the circularisation, degradation, and localization of circRNA is not fine-tuned, the expression of circRNA will be disturbed leading to cancer progression. Ultimately, the main focus of research should be on how circRNAs could be utilized clinically in cancer treatment. circRNAs have shown varying expression patterns in cancer patients suggesting circRNAs as promising diagnostic and prognostic markers. However, the discovery of circRNAs is still in its juvenile phase and more elaborative studies should be done for the screening of circRNAs in cancer samples. The past decade has also observed the role of natural products and phytochemicals in the treatment of several diseases including cancer (Singh et al., 2019; Singh et al., 2021b). In addition, the role of phytochemicals in the modulation of ncRNAs involved in chronic diseases has also been reported (Zhang et al., 2021). Therefore, the development of phytochemical-based novel strategies to target circRNAs could be beneficial in managing this disease. Also, a detailed understanding of the mode of action of circRNAs and the circRNA mediated modulation of miRNA and other downstream targets need to be focused on. With more technological advancements and a precise understanding of the circRNA-miRNA-TF regulatory axis, the advancement of circRNA based cancer therapeutics will be boosted and this will help in solving the confusing carcinoma puzzle a little bit more. In this direction, nano-enabled strategies could play an important role. In conclusion, this comprehensive review will contribute to enhancing the present-day knowledge related to the circRNA-miRNA-TF axis in cancer pathogenesis and development.

AUTHOR CONTRIBUTIONS

DS: writing—original draft. HS: writing—review and editing. NA: resources. HS: visualization. PK: supervision. All authors contributed to the article and approved the submitted version.

FUNDING

The Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, Saudi Arabia, has funded this project under Grant No. (FP-88-42) to NA.

ACKNOWLEDGMENTS

DS is thankful to UGC, India for providing Junior Research fellowship. HS is thankful to the UGC and DST-SERB New Delhi.

REFERENCES

Abdelmohsen, K., Panda, A. C., Munk, R., Grammatikakis, I., Dudekula, D. B., De, S., et al. (2017). Identification of HuR Target Circular RNAs Uncovers Suppression of PARP1 Translation by CircPABPN1. RNA Biol. 14 (3), 361–369. doi:10.1080/15476286.2017.1299788

Apte, R. S., Chen, D. S., and Ferrara, N. (2019). VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 176 (6), 1248–1264. doi:10.1016/j.cell.2019.01.021

Ashwal-Fluss, R., Meyer, M., Pamudurti, N. R., Ivanov, A., Bartok, O., Hanan, M., et al. (2014). circRNA Biogenesis Competes with Pre-mRNA Splicing. Mol. Cell 56 (1), 55–66. doi:10.1016/j.molcel.2014.08.019

Auferio, S., Beckman, Y. J., Pinto, Y. M., and Cremer, E. E. (2019). Circular RNAs Open a New Chapter in Cardiovascular Biology. Nat. Rev. Cardiol. 16 (8), 503–514. doi:10.1038/s41569-019-0185-2

Bachmair-Heyda, A., Reiner, A. T., Auer, K., Sulhabaatar, N., Aust, S., Bachельer-Hofmann, T., et al. (2015). Correlation of Circular RNA Abundance with Proliferation-Exemplified with Colorectal and Ovarian Cancer, Idiopathic Lupus Fibrosis, and normal Human Tissues. Sci. Rep. 5, 8057. doi:10.1038/srep08057

Bi, W., Huang, J., Nie, C., Liu, B., He, G., Han, J., et al. (2018). CircRNA circRNA_102171 Promotes Papillary Thyroid Cancer Progression through Modulating CTNNB1-dependent Activation of β-catenin Pathway. J. Exp. Clin. Cancer Res. 37 (1), 275. doi:10.1186/s13046-018-0936-7

Bonizzato, A., Gaffo, E., Te Kronnie, G., and Borluzzi, S. (2016). CircRNAs in Hepatoposis and Hematological Malignancies. Blood Cancer J. 6, e483. doi:10.1038/bcj.2016.81

Califf, R. M. (2018). Biomarker Definitions and Their Applications. Exp. Biol. Med. (Maywood) 243 (3), 213–221. doi:10.1177/1535370217750088

Chen, F., Wang, X., Fu, S., Wang, S., Fu, Y., Zhang, J., et al. (2020b). Circular RNA Circ-CDYL Sponges miR-1180 to Elevate Yes-Associated Protein in Multiple Myeloma. Exp. Biol. Med. (Maywood) 245, 925–932. doi:10.1177/1535370220918191

Chen, G., Shi, Y., Liu, M., and Sun, J. (2018). circHIPK3 Regulates Cell Proliferation and Migration by Sponging miR-124 and Regulating AQP3 Expression in Hepatocellular Carcinoma. Cell Death Dis. 9 (2), 175. doi:10.1038/s41419-017-0204-3

Chen, J. J., Lei, P., and Zhou, M. (2020a). hsa_circ_0121582 Inhibits Leukemia Growth by Dampening Wnt/β-Catenin Signaling. Clin. Transl Oncol. 22 (12), 2293–2302. doi:10.1007/s12094-020-02377-9

Chen, L. L. (2016). The Biogenesis and Emerging Roles of Circular RNAs. Nat. Rev. Mol. Cell Biol. 17 (4), 205–211. doi:10.1038/nrm.2015.32

Chen, M., Ai, G., Zhou, J., Mao, W., Li, H., and Guo, J. (2019). circMTO1 Promotes Tumorigenesis and Chemoresistance of Cervical Cancer via Regulating miR-6893. Biomed. Pharmacother. 117, 109064. doi:10.1016/j.biopha.2019.109064

Frontiers in Pharmacology | www.frontiersin.org January 2022 | Volume 12 | Article 784801
Chen, W., Quan, Y., Fan, S., Wang, H., Liang, J., Huang, L., et al. (2020). Exosome- transmitted circular RNA Hsa_circ_0051433 Suppresses Hepatocellular Carcinoma Progression. *Cancer Lett.* 475, 119–128. doi:10.1016/j.canlet.2020.01.022

Chen, X., Chen, R. X., Wei, W. S., Li, Y. H., Feng, Z. H., Tan, L., et al. (2018). PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition. *Clin. Cancer Res.* 24 (24), 6319–6330. doi:10.1158/1078-0432.CCR-18-1270

Conn, S. J., Pillman, K. A., Toubia, J., Conn, V. M., Salmanidis, M., Phillips, C. A., et al. (2015). The RNA Binding Protein Quaking Regulates Formation of circRNAs. *Cell* 160 (6), 1125–1134. doi:10.1016/j.cell.2015.02.014

Dahl, M., Husby, S., Eskelund, C. W., Besenbacher, S., Fjelstrup, S., Côme, C., et al. (2021). Expression Patterns and Prognostic Potential of Circular RNAs in Mantle Cell Lymphoma: a Study of Younger Patients from the MCL2 and MCL3 Clinical Trials. *Leukemia* [Online ahead of print]. doi:10.1038/s41375-021-01311-4

Dang, R. Y., Liu, F. L., and Li, Y. (2017). Circular RNA Hsa_circ_0010729 Regulates Negative Breast Cancer by Regulating the miR-330-3p/Myc Axis. *Onco Targets Ther.* 13, 1019–10159. doi:10.2147/OTT.S247547

Heldin, C. H., and Moustakas, A. (2012). Role of Smads in TGFβ Signaling. *Cell Tissue Res.* 347 (1), 21–36. doi:10.1007/s00441-011-1190-x

Ho, T. T., Zhou, N., Huang, J., Koirala, P., Xu, M., Fung, R., et al. (2015). Targeting Non-coding RNAs with the CRISPR/Cas9 System in Human Cell Lines. *Nucleic Acids Res.* 43, e17. doi:10.1093/nar/gku1198

Hollande, C., Boussier, J., Ziai, J., Nozawa, T., Bondet, V., Phung, W., et al. (2019). Inhibition of the Dipeptidyl Peptidase DPP4 (CD26) Reveals IL-33-dependent Eosinophil-Mediated Control of Tumor Growth. *Nat. Immunol.* 20 (3), 257–264. doi:10.1038/s41590-019-0321-5

Hsiao, K. Y., Lin, Y. C., Gupta, S. K., Chang, N., Yen, L., Sun, H. S., et al. (2017). Noncoding Effects of Circular RNA CXCDC66 Promote Colon Cancer Growth and Metastasis. *Cancer Sci.* 77 (9), 2339–2350. doi:10.1108/14772558201701457

Hsu, M. T., and Coca-Prados, M. (1979). Electron Microscopic Evidence for the Circular Form of RNA in the Cytoplasm of Eukaryotic Cells. *Nature* 280 (5720), 339–340. doi:10.1038/280339a0

Huang, W., Fang, K., Chen, T. Q., Zeng, Z. C., Sun, Y. M., Han, C., et al. (2019). circularRNAcircAF4 Functions as an Oncogene to Regulate MLL-AF4 Fusion Protein Expression and Inhibit MLL Leukemia Progression. *J. Hematol. Oncol.* 12, 103. doi:10.1186/s13045-019-0800-z

Huang, W., Yang, Y., Wu, J., Niu, Y., Yao, Z., Zhang, J., et al. (2020). Circular RNA cESRP1 Sensitizes Small Cell Lung Cancer Cells to Chemotherapy by Sponging miR-93-5p to Inhibit TGF-β Signalling. *Cell Death Dis.* 27 (5), 1709–1727. doi:10.1038/s41418-019-0455-2

Huang, X. Y., Huang, Z. L., Xu, Y. H., Zheng, Q., Chen, Z., Song, W., et al. (2017). Comprehensive Circular RNA Profiling Reveals the Regulatory Role of the circularRNA-c100338/miR-141-3p Pathway in Hepatitis B-Related Hepatocellular Carcinoma. *Sci. Rep.* 7 (1), 5428. doi:10.1038/s41598-017-05432-8

Huang, X. Y., Zhang, P. F., Wei, C. Y., Peng, R., Lu, J. C., Gao, C., et al. (2020). Circular RNA circMET Drives Immunosuppression and Anti-PD1 Therapy Resistance in Hepatocellular Carcinoma via the miR-30-5p/snaPPDA axis. *Cancer Sci.* 101 (9), 2266–2274. doi:10.1111/cas.14129

Jeck, W. R., Sorrentino, J. A., Wang, K., Slevin, M. K., Burd, C. E., Liu, J., et al. (2013). Circular RNAs Are Abundant, Conserved, and Associated with ALU Repeats. *RNA* 19 (2), 141–157. doi:10.1261/rna.035667.112

Jost, I., Shalamova, L. A., Gerresheim, G. K., Niepmann, M., Bindereif, A., and Rossbach, O. (2018). Functional sequestration of microRNA-122 from Hepatitis C Virus by Circular RNA Sponges. *RNA Biol.* 15, 1032–1039. doi:10.1080/15476286.2018.1435248

Jung, H. M., Phillips, B. L., Patel, R. S., Cohen, D. M., Jakymiw, A., Kong, W. W., et al. (2012). Keratinization-associated miR-7 and miR-21 Regulate Tumor Suppressor Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Oral Cancer. *J. Biol. Chem.* 287, 29261–29272. doi:10.1074/jbc.M112.366518

Kaminski, B., and Cyranowski, S. (2020). Recent Advances in Understanding Mechanisms of TGF Beta Signaling and its Role in Glioma Pathogenesis. *Adv. Exp. Med. Biol.* 1202, 179–201. doi:10.1007/978-3-030-36511-9_9

Ke, E. E., and Wu, Y. L. (2016). EGFR as a Pharmacological Target in EGFR-Mutant Non-small-cell Lung Cancer: Where Do We Stand Now? *Adv. Exp. Med. Biol.* 887, 390–401. doi:10.1007/978-3-030-36511-9_9

Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., et al. (2008). microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-Regulated in Glioblastoma. *Cancer Res.* 68, 3566–3572. doi:10.1158/0008-5472.CAN-07-6639

Khan, M. A., Singh, D., Ahmad, M., and Siddique, H. R. (2021). Revisiting Inorganic Nanoparticles as Promising Therapeutic Agents: A Paradigm Shift in Oncological Theranostics. *Eur. J. Pharm. Sci.* 164, 105892. doi:10.1016/j.ejps.2021.105892
Shi, X., Wang, B., Feng, X., Xu, Y., Lu, K., and Sun, M. (2020). circRNAs and Exosomes: A Mysterious Frontier for Human Cancer. *Mol. Ther. Nucleic Acids* 19, 384–392. doi:10.1016/j.omtn.2019.11.023

Shibue, T., and Weinberg, R. A. (2017). EMT, CSCs, and Drug Resistance: the Mechanistic Link and Clinical Implications. *Nat. Rev. Clin. Oncol.* 14 (10), 611–629. doi:10.1038/nrclinone.2017-44

Singh, D., Khan, M. A., and Siddique, H. R. (2021). Role of P53-miRNAs Circuitry in Immune Surveillance and Cancer Development: A Potential Avenue for Therapeutic Intervention. *Semin. Cell Dev Biol [Online ahead of print]*, S1084-9521(21)00076-0. doi:10.1016/j.secmdb.2021.04.003

Singh, D., Khan, M. A., and Siddique, H. R. (2021). Emerging Role of Long Non-coding RNAs in Cancer Chemoresistance: Unravelling the Multifaceted Role and Prospective Therapeutic Targeting. *Mol. Biol. Rep.* 47, 5569–5580. doi:10.1007/s11033-020-05609-x

Singh, D., Khan, M. A., and Siddique, H. R. (2022). Role of P53-miRNAs Circuitry in Immune Surveillance and Cancer Development: A Potential Avenue for Therapeutic Intervention. *Semin. Cell Dev Biol* [Online ahead of print], S1084-9521(21)00076-0. doi:10.1016/j.secmdb.2021.04.003

Teng, F., Xu, J., Zhang, M., Liu, S., Gu, Y., Zhang, M., et al. (2019). Comprehensive Circular RNA and Gene Expression Profiles in Gastric Cancer Based on Microarray Chip Technology. *Oncol. Rep.* 37 (3), 1804–1814. doi:10.3892/or.2017.5415

Wang, N., Gu, Y., Li, L., Wang, F., Lv, P., Xiong, Y., et al. (2018). Circular RNA Hsa_circ_0008305 (circPTK2) Inhibits TGF-β-mediated Transactivation of YY1. *Cancer Res.* 78 (3), 557–571. doi:10.1158/0008-5472.CAN-17-3920

Yang, W., Du, W. W., Li, X., Yee, A. J., and Yang, B. B. (2016). Foxo3 Activity Promoted by Non-coding Effects of Circular RNA and Foxo3 Pseudogene in the Inhibition of Tumor Growth and Angiogenesis. *Oncogene* 35 (30), 3919–3931. doi:10.1038/onc.2015.460

Yang, Y., Yao, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., et al. (2017). Extensive Translation of Circular RNAs Driven by N6-Methyladenosine. *Cell 27* (5), 626–641. doi:10.1038/cr.2017.31

Yang, Y., Gao, X., Zhang, M., Yang, Y., Sun, C., Xiao, F., et al. (2018). Novel Role of FBXW7 Circular RNA in Repressing Glial Tumorigenesis. *J. Natl Cancer Inst.* 110 (3), 304–315. doi:10.1093/jnci/djx166

Yang, Z., Qu, C. B., Zhang, Y., Zhang, W. F., Wang, D. D., Gao, C. C., et al. (2019). Disregulation of P53-RBM25-Mediated circAMOTL1L Biogenesis Contributes to Prostate Cancer Progression through the circAMOTL1L-miR-193a-5p-Pcda Pathway. *Oncogene* 38 (14), 2516–2523. doi:10.1038/s41388-018-0602-8

Yao, Y., Hua, Q., and Zhou, Y. (2019). Circular RNA Has_circ_0006427 Suppresses the Progression of Lung Adenocarcinoma by Regulating miR-6783-3p/DKK1 axis and Inactivating Wnt/β-Catenin Signaling Pathway. *Biochem. Biophys. Res. Commun.* 508 (1), 37–45. doi:10.1016/j.bbrc.2018.11.079

Ye, F., Gao, Z., Zhou, Y., Zhang, S., Zhang, L., Ou, X., et al. (2019). Circular RNA F-circSR Derived from SLC34A2-ROS1 Fusion Gene Promotes Cell Migration in Non-small Cell Lung Cancer. *Mol. Ther. Nucleic Acids* 10, 98–102. doi:10.1016/j.omtn.2019.05.004

Ye, F., Gao, Z., Zhou, Y., Zhang, S., Zhang, L., Ou, X., et al. (2019). Circular RNA F-circSR Derived from SLC34A2-ROS1 Fusion Gene Promotes Cell Migration in Non-small Cell Lung Cancer. *Mol. Ther. Nucleic Acids* 10, 98–102. doi:10.1016/j.omtn.2019.05.004

Yi, Z., Li, Y., Wu, Y., Zeng, B., Li, H., Ren, G., et al. (2020). Circular RNA 0001073 Attenuates Malignant Biological Behaviours in Breast Cancer Cell and is Delivered by Nanoparticles to Inhibit Mice Tumour Growth. *Onco Targets Ther.* 13, 6157–6169. doi:10.2147/OTT.S248822
You, X., Vlatkovic, I., Babic, A., Will, T., Epstein, I., Tushev, G., et al. (2015). Neural 
Circular RNAs Are Derived from Synaptic Genes and Regulated by 
Development and Plasticity. Nat. Neurosci. 18, 603–610. doi:10.1038/nn.3975

Zeng, K., He, B., Yang, B. B., Xu, T., Chen, X., Xu., M., et al. (2018). The Pro-
metastasis Effect of circANKS1B in Breast Cancer. Mol. Cancer 17 (1), 160. 
doi:10.1186/s12943-018-0914-x

Zhai, Z., Fu, Q., Liu, C., Zhang, X., Jia, P., Xia, P., et al. (2019). Emerging Roles of 
Hsa-Circ-0046600 Targeting the miR-640/HIF-1α Signalling Pathway in the 
Progression of HCC. Onco Targets Ther. 12, 9291–9302. doi:10.2147/ 
OTT.S229514

Zhang, C., Huo, S. T., Wu, Z., Chen, L., Wen, C., Chen, H., et al. (2020). Rapid 
development of Targeting circRNAs in Cardiovascular Diseases. Mol. Ther. 
Nucleic Acids 21, 568–576. doi:10.1016/j.omtn.2020.06.022

Zhang, G., and Zhang, G. (2019). Upregulation of FoxP4 in HCC Promotes 
Migration and Invasion through Regulation of EMT. Oncol. Lett. 17 (4), 
3944–3951. doi:10.3892/ol.2019.10049

Zhang, H., Wang, G., Ding, C., Liu, P., Wang, R., Ding, W., et al. (2017). 
Increased Circular RNA UBAP2 Acts as a Sponge of miR-143 to Promote 
Osteosarcoma Progression. Oncotarget 8 (37), 61687–61697. 
doi:10.18632/oncotarget.18671

Zhang, M., Huang, N., Yang, X., Luo, J., Yan, S., Xiao, F., et al. (2018a). A Novel 
Protein Encoded by the Circular Form of the SHPRH Gene Suppresses Glioma 
Tumorigenesis. Oncogene 37 (13), 1805–1814. doi:10.1038/s41388-017-0019-9

Zhang, M., Zhao, K., Xu, X., Yang, Y., Yan, S., Wei, P., et al. (2018b). A Peptide 
Encoded by Circular Form of LINC-PINT Suppresses Oncogenic 
Transcriptional Elongation in Glioblastoma. Nat. Commun. 9 (1), 4475. 
doi:10.1038/s41467-018-06862-2

Zhang, S., Long, F., Lin, H., Wang, X., Jiang, G., and Wang, T. (2021). 
Regulatory Roles of Phytochemicals on Circular RNAs in Cancer and 
Other Chronic Diseases. Pharmacol. Res. 174, 105936. doi:10.1016/j.
phr.2021.105936

Zhang, X., Luo, P., Jing, W., Zhou, H., Liang, C., and Tu, J. (2018c). circSMAD2 Inhibits 
the Epithelial–Mesenchymal Transition by Targeting miR-629 in Hepatocellular 
Carcinoma. Onco Targets Ther. 11, 2853–2863. doi:10.2147/OTT.S158008

Zhang, X., Wang, S., Wang, H., Cao, J., Huang, X., Chen, Z., et al. (2019). Circular 
RNA circNRP1 Acts as a microRNA-149-5p Sponge to Promote Gastric 
Cancer Progression via the AKT1/mTOR Pathway. Mol. Cancer 18 (1), 20. 
doi:10.1186/s12943-018-0935-5

Zhang, X. O., Wang, H. B., Zhang, Y., Lu, X., Chen, L. L., and Yang, L. (2014). 
Complementary Sequence-Mediated Exon Circularization. Cell 159 (1), 
134–147. doi:10.1016/j.cell.2014.09.001

Zhang, Y., Zhang, X. O., Chen, T., Xiang, J. F., Yin, Q. F., Xing, Y. H., et al. (2013). 
Circular Intronic Long Noncoding RNAs. Mol. Cell 51 (6), 792–806. 
doi:10.1016/j.molcel.2013.08.017

Zhang, Y., Zhao, H., and Zhang, L. (2018d). Identification of the Tumor-
suppressive Function of Circular RNA FOXO3 in Non-small C-cell L-ung 
Cancer through Spongeing miR-155. Mol. Med. Rep. 17 (6), 7692–7700. 
doi:10.3892/mmr.2018.8830

Zhao, W., Cui, Y., Liu, L., Qi, X., Liu, J., Ma, S., et al. (2020). Splicing Factor Derived 
Circular RNA circUHRF1 Accelerates Oral Squamous Cell Carcinoma 
Tumorigenesis via Feedback Loop. Cell Death Differ 27, 919–933. 
doi:10.1038/s41418-019-0423-5

Zhong, Z., Lv, M., and Chen, J. (2016). Screening Differential Circular RNA 
Expression Profiles Reveals the Regulatory Role of circTCF25-miR-103a-3p/ 
miR-107-CDK6 Pathway in Bladder Carcinoma. Sci. Rep. 6, 30919. doi:10.1038/ 
srep30919

Zhou, P., Xie, W., Huang, H. L., Huang, R. Q., Tian, C., Zhu, H. B., et al. (2020). 
circRNA_100859 Functions as an Oncogene in colon Cancer by Sponging the 
microRNA-217-HIF-1α Pathway. Aging (Albany NY) 12 (13), 13338–13353. 
doi:10.18632/aging.103438

Zhu, Q., Lu, G., Luo, Z., Gui, F., Wu, J., Zhang, D., et al. (2018). CircRNA 
Circle_0067934 Promotes Tumor Growth and Metastasis in Hepatocellular 
Carcinoma through Regulation of miR-1324/FGZD5/Wnt/β-Catenin axis. 
Biochem. Biophys. Res. Commun. 497 (2), 626–632. doi:10.1016/j.
biochem.2018.02.119

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Singh, Kesharwani, Alhakamy and Siddique. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.